Initial top-line results from a Phase III study of bromfenac ophthalmic solution (Remura, ISTA Pharmaceuticals) indicate that bromfenac was not statistically superior to placebo in treating one sign and one symptom of dry eye disease. ISTA announced this result from the WEST study, the first of two phase III safety and efficacy studies being conducted under a special protocol assessment (SPA) agreed upon with the FDA.
Bausch + Lomb (B + L) has expanded its voluntary recall of methylcellulose lubricant ophthalmic solution, USP 1% (Murocel) to six lots. Following this voluntary product recall, B + L will discontinue the product entirely.
Y. Ralph Chu, MD, has been named one of the top 10 business owners in the Twin Cities in the Minneapolis/St. Paul Business Journal Diversity in Business Awards program.
MoralEyes, a wholesaler and retailer of reading glasses and sunglasses, is launching a used-glasses recycling program Aug. 13 and 14 in New York City.
In an effort to assess and address the vision-related effects of the increased use of technology in learning environments, the American Optometric Association (AOA) has conducted a survey and released a report.
A $495,000 grant from the Juvenile Diabetes Research Foundation (JDRF) will help researchers at the University of Tennessee Health Science Center further research an eye drop that one day could be used to prevent diabetic retinopathy (DR).
Endo Optiks is now selling a triple-function 23-gauge laser endoscope in the United States and internationally.
Given the global launch of a corneal inlay (Kamra) for the treatment of presbyopia and an investment by medical technology company Medtronic, AcuFocus says it has experienced significant procedural growth since 2010.
In honor of Cataract Awareness Month in August, EyeCare America, a public service program of the Foundation of the American Academy of Ophthalmology (AAO), is providing eye exams at no out-of-pocket cost to some people aged 65 or more years.
The National Institute for Health and Clinical Excellence (NICE), an independent advisory organization in England, has recommended use of a 0.7-mg dexamethasone intravitreal implant in an applicator (Ozudex, Allergan) for the treatment of macular edema due to central retinal vein occlusion (CRVO) as well as for branch retinal vein occlusion (BRVO) in cases in which laser photocoagulation is neither beneficial nor appropriate.
The Centre for Contact Lens Research and the Brien Holden Vision Institute have launched www.contactlensupdate.com, a new source of Web-based information about contact lenses.
The Optical Laboratories Association (OLA) again will hold its annual meeting in conjunction with International Vision Expo West. Registration for the OLA 2011 annual meeting, which will be held Sept. 22 to 24 at the Sands Expo Convention Center in Las Vegas, is now open.
The International Vision Expo & Conference has announced new initiatives and discounts to help international visitors get the most out of the show, the educational sessions, and the host city.
Vision West Inc. and C&E Vision Services Inc. will host a Webinar, ?Yelp 101: Maximizing Yelp?s Business Tools to Attract New Patients? on Thursday, Aug. 11, at 8 pm Eastern Time, 5 pm Pacific Time. The Webinar is part of an ongoing initiative by Vision West and C&E to provide eye-care professionals with relevant social media resources.
Presbyopic spectacle correction is not necessary when performing visual field testing using automated perimetry in pseudophakic patients with a diffractive aspheric multifocal IOL implanted.
Simplification of PPV to repair primary rhegmatogenous retinal detachments means less is more.
Most American ophthalmologists recognize Aravind for its service for indigent patients.
The author muses on how the government's massive debt is leading federal leaders to desire to control the healthcare system.
Robert H. Osher, MD, loves teaching but he bristles at the restrictions that come with some meetings and their CME providers.
New treatment options for non-arteritis anterior ischemic optic neuropathy still are being developed.
Monthly intravitreal injections of ranibizumab for CRVO is effective, but careful, long-term observation is often necessary to maintain a positive treatment benefit when shifting to an as-needed treatment regimen.
James T. Rosenbaum, MD, has dedicated his career to ferreting out the secrets surrounding human leukocyte antigen B27 and its association with ankylosing spondylitis.
Optimal treatment and management of patients with idiopathic intracranial hypertension is currently unknown.
Breakthroughs in genetics and genomics will change our view of biology in coming decades, helping identify the causes of all single-gene eye diseases, gain insight into disease gene functions, untangle the genetics of common eye diseases, and bring the promise-and potential downsides-of personalized medicine into the clinic.
Investigators working with a new method of analysis based on topical coenzyme Q10, a molecule shown to have neuroprotective activity, have successfully profiled different phases of cell death in vivo.
Analyses of data collected during 4 years of follow-up in a prospective, multicenter European study demonstrate a favorable safety profile for the foldable, acrylic, angle-supported phakic IOL, including maintenance of corneal endothelial health.
A successful research career often includes a little serendipity as well as dedicated pursuit of a hypothesis, according to Andrew J. Fischer, PhD.
From potential new therapies for glaucoma and diabetic macular edema to a deeper look at the anterior segment the 2011 meeting of ARVO was, yet again, an industry spectacle.
The Bascom Palmer Eye Institute at the University of Miami and the Wilmer Eye Institute at Johns Hopkins Hospital, Baltimore, have been named to the first and second spots, respectively, in the ophthalmology category of U.S. News and World Report?s 2011?2012 list of best hospitals for the eighth consecutive year.
Pfizer has withdrawn its application to the European Medicines Agency for an extension of the therapeutic indication for 0.3-mg pegaptanib sodium (Macugen) injection to include treatment of visual impairment due to diabetic macular edema (DME).
